1. Home
  2. DRIO vs XLO Comparison

DRIO vs XLO Comparison

Compare DRIO & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DarioHealth Corp.

DRIO

DarioHealth Corp.

HOLD

Current Price

$7.30

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$9.00

Market Cap

49.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRIO
XLO
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
49.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
DRIO
XLO
Price
$7.30
$9.00
Analyst Decision
Strong Buy
Buy
Analyst Count
2
1
Target Price
$35.00
$28.00
AVG Volume (30 Days)
5.4K
26.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
1559.02
N/A
EPS
1.25
N/A
Revenue
$7,394,000.00
$43,766,000.00
Revenue This Year
$20.27
N/A
Revenue Next Year
$47.58
$168.77
P/E Ratio
$5.67
N/A
Revenue Growth
43.02
589.88
52 Week Low
$0.38
$0.46
52 Week High
$17.74
$9.25

Technical Indicators

Market Signals
Indicator
DRIO
XLO
Relative Strength Index (RSI) 36.51 65.76
Support Level $6.16 $7.47
Resistance Level $9.46 N/A
Average True Range (ATR) 0.37 0.50
MACD -0.05 0.07
Stochastic Oscillator 11.00 87.24

Price Performance

Historical Comparison
DRIO
XLO

About DRIO DarioHealth Corp.

DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: